Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
TABUTEAU HERRIOT reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that Chief Executive Officer Herriot Tabuteau received a grant of 54,623 restricted stock units. Each RSU represents a contingent right to receive one share of Axsome common stock.
According to the award terms, 25% of the RSUs vest on the one-year anniversary of the grant date, with the remaining units vesting in three substantially equal annual installments so that all RSUs are fully vested on February 26, 2030. Vested shares will be delivered to Tabuteau upon the earlier of a qualifying change in control of Axsome, his separation of service (including certain terminations, death, or disability), or seven years from the grant date.
Pizzie Nick reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that its Chief Financial Officer, Nick Pizzie, received a grant of 18,570 Restricted Stock Units (RSUs) on February 26, 2026. Each RSU represents a contingent right to receive one share of Axsome common stock.
According to the award terms, 25% of the RSUs vest on the one-year anniversary of the grant date, with the remaining units vesting in three substantially equal annual installments so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered upon the earlier of a qualifying change in control, the CFO’s separation of service under specified conditions, or seven years from the grant date.
Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics reported that its General Counsel, Hunter R. Murdock, received a grant of 16,385 restricted stock units (RSUs) of company common stock. Each RSU represents a right to receive one share at a future date.
According to the award terms, 25% of the RSUs will vest on the one-year anniversary of the grant date. The remaining units will vest in three substantially equal annual installments, so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered to Murdock upon the earlier of a qualifying change in control, his separation from the company (including termination, death, or total and permanent disability), or seven years from the grant date.
Maizel Ari reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics Chief Commercial Officer Ari Maizel received a grant of 16,385 restricted stock units (RSUs) of company common stock. Each RSU represents the right to receive one share in the future, subject to vesting and service conditions.
According to the award terms, 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three substantially equal annual installments so that the award is fully vested on February 26, 2030. Shares will be delivered to Maizel upon the earlier of a qualifying change in control, his separation of service under specified conditions, or seven years from the grant date.
Jacobson Mark L. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics awarded Chief Operating Officer Mark L. Jacobson 19,663 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. This is an equity-based compensation grant, not an open-market share purchase or sale.
25% of the RSUs will vest on the one-year anniversary of the grant date. The remaining units will vest in three substantially equal annual installments so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered upon the earlier of a qualifying change in control, Jacobson’s separation of service (including certain terminations, death, or total and permanent disability), or seven years from the grant date.
Axsome Therapeutics director Mark Coleman reported an open‑market sale of 25,000 shares of common stock. The sale occurred on
The sold shares were underlying stock from previously exercised options. After this transaction, Coleman holds 47,140 Axsome shares directly. He is also deemed to beneficially own 403,856 additional shares indirectly through an entity over which he has voting and dispositive power.
Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported option-related transactions in company stock. On
He then sold the resulting 35,378 common shares in open-market transactions at a weighted average price of
AXSM affiliate intends to sell 35,378 shares of Class A Common stock on 02/26/2026. The shares were acquired as compensation (stock options) and the planned method is a cashless exercise / same-day sale through Goldman Sachs & Co. LLC.
Axsome Therapeutics, Inc. director Mark Coleman reported exercising stock options and holding the resulting shares. On February 23, 2026, he exercised options covering 6,250 shares of common stock at $4.95 per share for cash, and kept the underlying shares rather than selling them. Following these transactions, he directly owned 72,140 shares of Axsome common stock and indirectly beneficially owned 403,856 shares held through an entity over which he has voting and dispositive power.
Axsome Therapeutics director Mark Coleman exercised stock options and increased his share exposure to the company. On February 20, 2026, he exercised 12,485 stock options at an exercise price of $4.95 per share for cash, receiving the same number of Axsome common shares, which he held rather than selling.
After the transactions, Coleman holds 65,890 shares of common stock directly and 13,971 stock options directly. He is also reported as the indirect beneficial owner of 403,856 common shares held by an entity over which he has voting and dispositive power.